loading page

Characterization of Omalizumab Updosing Patterns and Predictive Factors in Chronic Spontaneous Urticaria : A Prospective Multicentric Observational Study.
  • +9
  • Guillaume PIERRARD,
  • Claire Bernier ,
  • AURELIE DU-THANH,
  • Corina BARA,
  • Angele Soria,
  • Florence Castelain,
  • Isabelle Boccon-Gibod,
  • Florence Hacard,
  • Juliette DELAUNAY,
  • Laurence De Montjoye,
  • Delphine STAUMONT-SALLE,
  • Frédéric Dezoteux
Guillaume PIERRARD
Centre Hospitalier Universitaire de Lille Service de Dermatologie

Corresponding Author:[email protected]

Author Profile
Claire Bernier
Societe Francaise des Lasers en Dermatologie
Author Profile
AURELIE DU-THANH
Societe Francaise des Lasers en Dermatologie
Author Profile
Corina BARA
Societe Francaise des Lasers en Dermatologie
Author Profile
Angele Soria
Societe Francaise des Lasers en Dermatologie
Author Profile
Florence Castelain
Societe Francaise des Lasers en Dermatologie
Author Profile
Isabelle Boccon-Gibod
Societe Francaise des Lasers en Dermatologie
Author Profile
Florence Hacard
Societe Francaise des Lasers en Dermatologie
Author Profile
Juliette DELAUNAY
Societe Francaise des Lasers en Dermatologie
Author Profile
Laurence De Montjoye
Societe Francaise des Lasers en Dermatologie
Author Profile
Delphine STAUMONT-SALLE
Centre Hospitalier Universitaire de Lille Service de Dermatologie
Author Profile
Frédéric Dezoteux
Centre Hospitalier Universitaire de Lille Service de Dermatologie
Author Profile

Abstract

Background: Limited information is available on the use of omalizumab (OMA) updosing since its introduction as a second-line therapy in chronic spontaneous urticaria (CSU) in 2014. Practical guidelines from health authorities are lacking, and the specific characteristics of patients requiring higher doses remain unknown. Our objectives were to characterize the patterns of OMA updosing (defined as changes in dose and/or injection intervals), to identify the predictive factors associated with updosing, and to improve CSU management. Methods: We conducted a prospective, multicentric, real-life, observational study, including patients diagnosed with CSU and starting OMA. The data were collected at 0, 3, 6 and 9 months. The primary endpoint was the frequency of OMA updosing at 3 months. The secondary endpoints included an analysis of updosed patients’ profile, and an assessment of OMA efficacy and safety. Results: We included 153 patients. Twenty percent of patients at M3 were updosed, and 27% in total during the 9-month follow-up. Practitioners mainly chose to increase the frequency of injections (66%). At baseline, the updosed patients were more likely, to have inducible urticaria (50% vs. 33%, p=0.046), more severe CSU (UCT 3 vs. 4, p<0.001; DLQI 14 vs. 11, p=0.040), a lower lymphocyte count (1894 vs. 2100, p=0.026) and IgE below 70 UI/mL (65% vs. 45%, p=0.039). The side effects of OMA were not more frequent after updosing. Conclusion: One in five patient underwent updosing within just three months. OMA updosing is frequent in particular in cases of severe disease, inducible urticaria and low IgE blood levels.
08 Mar 2024Submitted to Allergy
08 Mar 2024Submission Checks Completed
08 Mar 2024Assigned to Editor
10 Mar 2024Reviewer(s) Assigned
21 Mar 2024Review(s) Completed, Editorial Evaluation Pending
22 Mar 2024Editorial Decision: Revise Minor
09 May 20241st Revision Received
10 May 2024Submission Checks Completed
10 May 2024Assigned to Editor
02 Jun 20242nd Revision Received
04 Jun 2024Submission Checks Completed
04 Jun 2024Assigned to Editor
04 Jun 2024Review(s) Completed, Editorial Evaluation Pending
08 Jun 2024Reviewer(s) Assigned
08 Jun 2024Reviewer(s) Assigned
30 Jun 20243rd Revision Received
03 Jul 2024Submission Checks Completed
03 Jul 2024Assigned to Editor
04 Jul 2024Reviewer(s) Assigned
11 Jul 2024Review(s) Completed, Editorial Evaluation Pending
11 Jul 2024Editorial Decision: Accept